ABITEC’s R&D continues to develop innovative products that meet the ever evolving demands of the pharmaceutical market. The expansion of their non-ionic High HLB surfactant line, ACCONON®,offers a product that can be used in solid formulation as a high melt emulsifier and bioavailability enhancer. ABITEC is also introducing to market their first line of functional lipid excipients for parenteral applications, INJECTA™.
Rick Kettinger, Global Business Unit Director – Pharmaceutical and Nutritional Health for ABITEC said, “Utilizationof our core capabilities and expert technical staff to develop the right products for the market is what we do best. We strive to increase our customer’s formulating options, with high-quality products that meet the needs of their application.”
Technical highlights include:
ACCONON® C-50 EP/NF*
ACCONON® C-50 EP/NF is mixed mono-, di- and triglycerides of hydrogenated palm oil andMacrogol palmitate/stearateand meets the requirements of current European Pharmacopoeia (EP) and United States Pharmacopeia/National Formulary (USP/NF) Monographs for StearoylMacrogolglycerides / StearoylPolyoxylglycerides.
INJECTA™ Lipid Excipients*
The new INJECTA™ parenteral grade lipid excipients provideimproved solubilization for injectable actives. The INJECTA grade portfolio of products include; CAPTEX® medium chain triglycerides and CAPMUL® mono- and di- glycerides, manufactured specifically for use in injectable formulations. These products meetand comply with specified monographs**.
Abitec corporation, new innovations, dosage form applications
1.jpg)